LISBON, April 8 (Reuters) – Portugal will from now on recommend the AstraZeneca (AZN.L) COVID-19 vaccine only for people aged over 60, the health authority DGS said on Thursday, amid concerns over possible links between the shot and very rare cases of blood clots.
The coordinator of the vaccination taskforce, Henrique Melo, said the decision would only have a "small" impact on the vaccination rollout.
"I want to highlight the goal of the vaccination campaign in Portugal is to save lives and prevent serious illness," health authority head Graca Freitas told a news conference. "This can be achieved with any vaccine approved in Portugal."
The move came after the European Medicines Agency announced on Wednesday it had reports of 169 cases of a rare clotting disorder out of 34 million doses administered in Europe. Most occurred in women under 60 and within two weeks of injection. read more
Melo said Portugal had already administered 400,000 doses of the AstraZeneca vaccine.
Freitas urged those who had received a first dose to stay calm as the side effects were "extremely rare". The suspension for people under 60 is temporary and will be evaluated when there is more data available.
Portugal is expecting to receive another 1.4 million AstraZeneca doses by June. It also uses the Pfizer and Moderna vaccines.
Portugal, which fought the worst of its outbreak in January before cases slowed, has had 825,633 infections and 16,899 deaths.
European Union health ministers failed to agree common guidance on the use of the AstraZeneca vaccine, despite calls for coordination across member states to combat any public hesitancy over taking the shot. read more
Our Standards: The Thomson Reuters Trust Principles.
Thomson Reuters
Portugal-based multimedia correspondent reporting on politics, economics, the environment and daily news. Previous experience in local journalism in the UK., co-founded a project telling the stories of Portuguese-speakers living in London, and edited a youth-led news site.
A UK court on Wednesday ordered GSK's Tesaro to pay rival AstraZeneca royalties on total sales of ovarian cancer drug Zejula, in a win for the Anglo-Swedish drugmaker.
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, national and international news to professionals via desktop terminals, the world's media organizations, industry events and directly to consumers.
Build the strongest argument relying on authoritative content, attorney-editor expertise, and industry defining technology.
The most comprehensive solution to manage all your complex and ever-expanding tax and compliance needs.
The industry leader for online information for tax, accounting and finance professionals.
Access unmatched financial data, news and content in a highly-customised workflow experience on desktop, web and mobile.
Browse an unrivalled portfolio of real-time and historical market data and insights from worldwide sources and experts.
Screen for heightened risk individual and entities globally to help uncover hidden risks in business relationships and human networks.
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2023 Reuters. All rights reserved